# Rareş-Petru Moldovan

Pyrrole-Imidazole Alkaloids from Marine Sponges: Structural Variation and Cytotoxicity of (–)-Dibromophakellstatin, Synthesis of Ugibohlin and Oroidin, and Studies Towards Oxocyclostylidol





Pyrrole-Imidazole Alkaloids from Marine Sponges: Structural
Variation and Cytotoxicity of (–)-Dibromophakellstatin,
Synthesis of Ugibohlin and Oroidin, and Studies Towards
Oxocyclostylidol





# Pyrrole-Imidazole Alkaloids from Marine Sponges: Structural Variation and Cytotoxicity of (–)-Dibromophakellstatin, Synthesis of Ugibohlin and Oroidin, and Studies Towards Oxocyclostylidol

Von der Fakultät für Lebenswissenschaften

der Technischen Universität Carolo-Wilhelmina

zu Braunschweig

zur Erlangung des Grades eines

Doktors der Naturwissenschaften

(Dr. rer. nat.)

genehmigte

Dissertation

von Rareş-Petru Moldovan

aus Turda / Rumänien



## Bibliografische Information der Deutschen Nationalbibliothek

Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Daten sind im Internet über http://dnb.d-nb.de abrufbar.

1. Aufl. - Göttingen: Cuvillier, 2012

Zugl.: (TU) Braunschweig, Univ., Diss., 2012

978-3-95404-228-9

1. Referent: Professor Dr. Thomas Lindel

2. Referent: Privatdozent Dr. Jörg Grunenberg

eingereicht am: 03.08.2011

mündliche Prüfung (Disputation) am: 02.11.2011

Druckjahr 2012

Dissertation an der Technischen Universität Braunschweig, Fakultät für Lebenswissenschaften

© CUVILLIER VERLAG, Göttingen 2012

Nonnenstieg 8, 37075 Göttingen

Telefon: 0551-54724-0

Telefax: 0551-54724-21

www.cuvillier.de

Alle Rechte vorbehalten. Ohne ausdrückliche Genehmigung des Verlages ist es nicht gestattet, das Buch oder Teile daraus auf fotomechanischem Weg (Fotokopie, Mikrokopie) zu vervielfältigen.

1. Auflage, 2012

Gedruckt auf säurefreiem Papier

978-3-95404-228-9



## Vorveröffentlichungen der Dissertation

Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für Lebenswissenschaften, vertreten durch den Mentor der Arbeit, in folgenden Beiträgen vorab veröffentlicht:

#### **Publikationen**

- Rareş-Petru Moldovan, Thomas Lindel, "Improved conversion of dihydrooroidin to oroidin and ugibohlin", *Z. Naturforsch., B: J. Chem. Sci.* 2009, 64b, 1612-1616.
- 2. Rareş-Petru Moldovan, Thomas Lindel, "Studies towards oxocyclostylidol", *manuscript in preparation*.
- Rareş-Petru Moldovan, Michael Zöllinger, Peter G. Jones, Gerhard Kelter, Heinz-Herbert Fiebig, Thomas Lindel, "Synthesis and cytotoxicity of ring C-functionalized derivatives of the marine natural product (–)dibromophakellstatin", Eur. J. Org. Chem. 2012, 4, 685–698.

#### **Tagungsbeiträge**

- Rareş-Petru Moldovan, Michael Zöllinger, Thomas Lindel "Medicinal Chemistry of (–)-Dibromophakellstatin" (poster communication). GDCh Wissenschaftsforum Chemie 2007, Ulm, Germany, 2007.
- Rareş-Petru Moldovan, Michael Zöllinger, Thomas Lindel "Medicinal Chemistry of (–)-Dibromophakellstatin" (oral and poster communication). Jungchemikertag 2007, Braunschweig, Germany, 2007.
- 3. Rareş-Petru Moldovan, Thomas Lindel: "Oxidation of Pyrrole-Imidazole Alkaloids" (oral communication). RICCCE XVI, Sinaia, Romania, 2009.



#### Acknowledgement

Foremost, I wish to express my deepest gratitude to my Ph.D. supervisor Prof. Dr. Thomas Lindel for giving me the opportunity to work in the excellent academic environment at the Institute of Organic Chemistry, on an exciting and intriguing topic of Marine Natural Products. I would like to thank him for the permanent support, helpful discussions and for the freedom for performing my scientific research.

I am thankful to Priv.-Doz. Dr. Jörg Grunenberg for agreeing to be co-referee of my thesis.

I thank Prof. Dr. H.-H. Fiebig and Dr. Gerhard Kelter from Oncotest GmbH, Freiburg for performing biological investigations of the dibromophakellstatin derivatives.

I would like to thank all former and present members of the Lindel group for the friendly and supportive environment. I am deeply indebted to all my students for helping me to complete this research. Furthermore I thank all the other chemistry research groups for sharing substances and ideas.

Thanks also to the staff of all analytical and technical departments and also to administrative and secretary staff of Institute of Organic Chemistry.

Special thanks are also directed to Dr. Ion Neda for encouragement and support in my scientific career.

In addition I would like to thank Deutsche Forschungsgemeinschaft for funding the research project and the Förderverein der Freunde des Instituts für Organische Chemie for support of conference participations.

Apart from my colleagues, I would like to thank my family and my friends, especially Daniela for always being there for me.



# **Table of Contents**

I. IN	TRODUCTION	1
1.	Summary	1
2.	Alkaloids	7
3.	Pyrrole-imidazole alkaloids	11
3.1.	The structures of the pyrrole-imidazole alkaloids	11
3.2.	Biological activity of (–)-dibromophakellstatin (33)	16
3.3.	Recent advances in the synthesis of the pyrrole-imidazole alkaloids	17
II. RE	SULTS AND DISCUSSION	23
1.	Synthesis of oroidin	23
1.1.	Synthesis of oroidin <i>via</i> Sonogashira coupling	23
1.2.	Synthesis of oroidin (8) by oxidation of dihydrooroidin (7)	28
2.	Oxidation of oroidin (8)	30
3.	Oxidation of <i>rac</i> -cyclooroidin ( <b>14</b> )	31
3.1.	Synthetic strategies for the oxidation of cyclooroidin (14)	33
3.2.	Study on a model molecule: oxidation of <i>rac</i> -longamide A (126)	40
3.3.	Degree of bromination of <i>rac</i> -cyclooroidin (14)	43
4.	Cyclization of dihydrooroidin (7) to rac-dibromophakellin (10)	46
4.1.	Oxidation of <i>rac</i> -dibromophakellin ( <b>10</b> )	48
4.2.	Separation of (–)- and (+)-dibromophakellin	50
5.	Synthesis of $\it rac-N$ -methyldibromoisophakellin (12) and ugibohlin (13) .	52
5.1.	Synthesis of dihydrosventrin (148) and sventrin (147)	53
5.2.	Isomerization of <i>rac</i> -dibromophakellin ( <b>10</b> )	55
5.3.	Synthesis of <i>rac-N</i> -methyldibromoisophakellin (12)	56
5.4.	Ring D opening to ugibohlin (13)	58
6.	Medicinal chemistry of (–)-dibromophakellstatin (33)	59
6.1.	SAR of selected pyrrole-imidazole alkaloids	59
6.2.	Acetylation of the hydroxy group	62
6.3.	Alkylation <i>via</i> deprotonation	63
6.4.	Alkylation <i>via</i> triflates	68
6.5.	Formation of 11,12-dehydrophakellstatin (179)	69
6.6.	Sml <sub>2</sub> -mediated deprotection of ether derivatives	73
6.7.	A click reaction	75



6	.8.	Biological activity of ring C functionalized dibromophakelistatin	
		derivatives	80
6	.9.	Cytotoxicity assays	81
6	.10.	Synthesis of 12 <i>R</i> -epimers	85
III.	EXF	PERIMENTAL SECTION	88
IV.	CR	YSTALLOGRAPHIC DATA	145
1.		Crystallographic data of 176	145
2.		Crystallographic data of 30	147
V.	APF	PENDIX	150
1.		Abbreviations	150
2.		References	151
3		Lebenslauf	165

0

#### I. Introduction

#### 1. Summary

# a. Synthesis and oxidation of oroidin and analogues

Oroidin is considered to be the biogenetic key metabolite of the pyrrole-imidazole alkaloids. Several syntheses are known to date, all of which contain steps with only moderate yields. For a study on its reactivity large quantities are needed. Therefore, an improved synthesis would be beneficial. In the present work two different known routes to 8 were investigated. By following the method developed in our group (*via* Sonogashira coupling) several analogues arose as new products. By treating the two deaminated analogs 1 and 4 with NBS in TFA, no cyclization to the phakellin skeleton 3 took place. Instead, pyrrole oxidation occurred (Scheme 1).

Scheme 1. Oxidation of oroidin analogues.

Alternatively, oroidin (8) was synthesized *via* dihydrooroidin (7) by modifying a procedure developed by Horne and co-workers. The yield of the oxidation step of 7 to 8 represented a great disadvantage of this approach. However, by treating 7 with an equimolar amount of *N*-chlorosuccinimide in DMF instead of MeOH, followed by warming up to 100 °C for one hour, oroidin (8) was formed in good yield (75%). The

2


reaction took place *via* chlorination of the 5-position on the 2-aminoimidazole followed by thermal elimination of hydrochloric acid (Scheme 2).

Several oxidation reactions were performed on oroidin (8) aiming at its conversion to more complex members of the family. Due to its high reactivity, complex product mixtures were formed or decomposition occurred. In a presumably biomimetic reaction with ammonium peroxodisulfate in an aqueous buffer the natural product dispacamide A (9) was formed in a quantitative manner.

Scheme 2. Improved conversion of 7 to oroidin (8) and oxidation to 9.

# b. Synthesis of ugibohlin and rac-N-methylisophakellin

Compound **7** was cyclized to *rac*-dibromophakellin (**10**) according to Horne's procedure and the reactivity of **10** was examined. Under oxidative reaction conditions, only pyrrole oxidation occurred. However, when **10** (the free base) was boiled in neutral or basic conditions (ammonia or Ba(OH)<sub>2</sub> aqueous solutions), isomerization to *rac*-dibromoisophakellin (**11**) took place (Scheme 3). By boiling the free base of **10** in water for 48 hours **11** was formed in a quantitative manner. *Rac-N*-methylisophakellin (**12**) was synthesized for the first time by treatment of **11** with NaH/MeI in good yield. When **11** was treated with 6 M hydrochloric acid for one hour at room temperature, the natural product ugibohlin (**13**) was obtained for the first time.



Scheme 3. Conversion of *rac*-dibromophakellin (10) to the natural products 11, 12 and 13.

#### c. Oxidation of rac-cyclooroidin

The biomimetic conversion of *rac*-cyclooroidin (14) to *rac*-oxocyclostylidol (112) was attempted. Initial efforts to introduce the olefinic double bond *via* dimethoxylation and elimination of methanol gave rise to the oxo compound 16, which could be oxidized further to the dispacamide-like compounds 17 and 18. Alternatively, 18 was formed directly from *rac*-cyclooroidin (14) in a much better yield (65%), together with small amount of 17 (10%, Scheme 25) by treatment with Pb(OAc)<sub>4</sub> in acetic acid. Upon irradiation at 300 nm for 30 minutes, the interconversion of 17 to 18 took place and an equilibrium ratio of 1:1 has been observed. Both 17 and 18 proved to be very stable and no further reaction was possible. The olefinic double bond was successfully introduced by the chlorination-dehydrochlorination procedure employing NCS and DMF, which had also worked for dihydrooroidin (7).

The oxidation of the pyrrole moiety proved to be difficult. The non-cyclized 2-aminoimidazole showed the much higher nucleophilicity. A favored oxidation product of cyclooroidin (14) employing different reagents was found to be 17 (Scheme 4). Several attempts were made in order to change the reactivity order of pyrrole versus 2-aminoimidazole. Boc-protection of the 2-aminoimidazole part of the

cyclooroidin (14) did not change the nucleophilicity of the 2-aminoimidazole at all. Also, removing the bromine atoms at the pyrrole unit did not increase its reactivity. Oxocyclostylidol (112) remains unsynthesized.

Scheme 4. Oxidation of cyclooroidin (14).

# d. Ring C functionalization of (–)-dibromophakellstatin (33)

Initial efforts to functionalize the ring C hydroxyl function of (–)-dibromohydroxyphakellstatin (34) were based on the classical Williamson method. On treatment of 19 with NaH in DMF, an unexpected nucleophilic attack at the ring D carbamate took place forming a new carbonate moiety at ring C (21, Scheme 5). By quenching the reaction with electrophiles like methyl iodide, selective ring D alkylation occurred. Upon  $Sml_2$ -mediated deprotection of 21 (–)-N-methylhydroxyphakellstatin (22) was obtained (Scheme 5).

It was discovered that ring C functionalization of (–)-dibromophakellstatin (33) is possible in high yield starting from the hydroxy intermediate 20 *via* the corresponding triflate. Several ethers of different size were synthesized (Scheme 5). The mechanism through which 33 is acting as a cytostatic is not known. Aiming at a better understanding, several derivatives suitable for immobilization on protein beads

and binding protein isolation were synthesized. The simpler one is derivative **32** that bears a terminal alkyne (Scheme 61). Upon binding to the tagged protein, **32** should be subject of a Click reaction with an azide placed on a solid support, followed by the identification of a binding protein.

Scheme 5. Synthesis of ring C-functionalized dibromophakellstatin derivatives.

Another derivative (35) contains a fluorescent moiety (Figure 1). It is designed for visual identification of a binding protein. Compound 35 is the first fluorescent pyrrole-imidazole alkaloid derivative synthesized. The third and most complex synthesized derivative (36) contains a biotin moiety and a photoreactive group (Figure 1). It was designed for immobilization on avidin or streptavidin beads upon incubation with a protein mixture. Upon irradiation, the photoreactive group should ensure the covalent binding to the tagged protein, by generating the highly reactive nitrene.




Figure 1. Schematic structures of the coumarine and biotine derivatives **35** and **36**.

The biological examination of the 12*S*-dibromohydroxyphakellstatin derivatives on twelve different cancer cell lines has shown no or low activity for the new derivatives. Only 12*R*-dibromohydroxyphakellstatin (**34**) exhibited cytotoxicity, with a medium value of IC $_{50}$  = 1.34  $\mu$ M compared to (–)-dibromophakellstatin (IC $_{50}$  = 10.5  $\mu$ M) (see Table 2). Low cytotoxicity was determined for the alkyne and coumarine (**32** and **35**, see Figure 17) derivatives and total activity loss was recorded for all other derivatives.

7

#### 2. Alkaloids

Natural products represent a large variety of compounds found in living organisms. Whereas primary metabolites (sugars and amino acids) occur in all living organisms, secondary metabolites are limited to certain organisms and fulfill special biological and chemical roles. Secondary metabolites are responsible for the strong differentiation of species within the same class of organism, concerning chemical defence, chemical communication or other biochemical physiological functions. Considerable differentiation between non-marine and marine secondary metabolites can be made. Whereas the natural products extracted from terrestrial sources represent a large variety of secondary metabolites, compounds with unusual chemical diversity have been isolated from marine life. Differences may be related to underwater pressure and the higher concentration of salt in the marine environment. Both marine and non-marine occurring natural products are investigated for biological activity in medicine. The difficult access to marine life is representing a great impediment, motivating scientists for research in the area of marine natural products.

Since ancient times Opium poppy and related plants (*Papaver somniferum*) have been used in medicine as analgesics.<sup>2</sup> However, the use of plants as medicinal drugs has a great drawback: the dose of the active compound cannot be precisely controlled. In 1806, morphine (**37** see Figure 2) was isolated from opium as a pure substance by Sertürner.<sup>3</sup> Although structural elucidation and synthesis of **37** were performed for the first time in the 20<sup>th</sup> century, it could be proven early that morphine (**37**) was responsible for the biological activity of the plant. Sertürner was the first scientist to isolate an active ingredient from a medicinal plant. A few years later a new class of compounds was established, called alkaloids, by the German chemist Carl F. W. Meissner.<sup>4</sup>




Figure 2. Morphine (37), coniine (38), and atropine (39).

Another early example is coniine (38), which is a poison found in the yellow pitcher plant and was isolated by Giesecke in 1827.<sup>5</sup> Its structural elucidation was carried out by Blyth and Hoffmann.<sup>6</sup> It was the first alkaloid to be synthesized in the laboratory by Ladenburg in 1886.<sup>7</sup> The synthesis starts from 2-methylpyridine which reacted with formaldehyde in the presence of a base in a Knoevenagel condensation followed by reduction with sodium in ethanol. Atropine (39) is a secondary metabolite extracted from the *Solanaceae* plants isolated in pure form in 1833 by Geiger and Hess. It has also been known since ancient times to be a drug with a wide variety of medicinal effects.

Several other alkaloids were also isolated in the 19<sup>th</sup> century like quinine and strychnine.<sup>8</sup> However, a large number of alkaloids have been isolated in the 20<sup>th</sup> century due to the development of new chromatographic and analytical methods. Along with terpenes and polyketides, alkaloids are widely spread in nature. Despite the fact that a large number of alkaloids are toxic, numerous pharmaceuticals found important applicability in medicine during the 20<sup>th</sup> century.

Only in the second half of the last century, the exploration of marine life attracted the attention of scientists. More than 22.000 marine natural products have been isolated to date. Usually the isolation of natural products is bioassay-guided, and only the bio-active and the preponderant compounds are isolated. The bioactive molecules might be carotenoids, terpenoids, guanidine derivatives, indoles, hence the preponderant compounds are isolated.

A large number of toxins have been isolated from marine organisms. Saxitoxin (41)<sup>16</sup> was isolated from the marine micro algae *Gonyaulax catenella* by Schantz and coworkers<sup>17</sup>. The structure of saxitoxin was assigned by X-ray crystallography.<sup>18</sup> It was shown to have an abnormal pK<sub>a</sub> value of 8.1 for one of the guanidinium subunit.<sup>19</sup> The lethal doses (LD<sub>50</sub>) to several animals are reported, including humans (death occurred upon ingestion of less than 1 mg of toxine).<sup>20</sup> Tetrodotoxin<sup>21</sup> occurs in both non-marine and marine bacteria<sup>22</sup> and it was first isolated in 1964 by several authors.<sup>23</sup> The structure of tetrodotoxin (40) was confirmed by single crystal X-ray diffraction studies by Woodward and coworkers.<sup>24</sup> Saxitoxin and tetrodotoxin are known to block the sodium channel in muscles and nerve.<sup>25</sup> Several toxins were isolated from the "red tide" dinoflagellate, *Karenia brevis* (formerly *Gymnodinium breve*), and named brevetoxines.<sup>26</sup> Brevetoxin A (Figure 3,

compound **42**)<sup>27</sup> appears to be the most toxic brevetoxine. The structural assignment was performed by NMR, IR, UV and MS and confirmed by X-ray analysis.<sup>28</sup>

Figure 3. The structures of tetrodotoxin (40), saxitoxin (41), and brevetoxin A (42).

Maitotoxin<sup>29</sup> (not depicted in the Figure 3) was also isolated from the toxic dinoflagellate *Karenia brevis*.<sup>28</sup> Maitotoxin<sup>29</sup> is one of the most impressive natural products with a molecular mass of 3421.6 Da (as disodium salt), being the largest natural product to be isolated except for biopolymers.<sup>30</sup> Mouse lethality occurred when very small doses of maitotoxin were administrated (0.13 μg/kg, intraperitoneal injection) and proved to be the most active toxin besides the proteinous toxins.<sup>30</sup> The structural elucidation represented a challenge, largely due to the signal overlapping.<sup>31</sup> The toxins are produced by seafood as self-defense against predatory.<sup>32</sup> Although most of the fishes are killed by the poisonous plankton, some survive becoming poisonous for humans.<sup>17</sup> The mode of action has largely been investigated but still is not fully understood.

Many bioactive secondary metabolites have great medicinal potential. Wakayin (43, Figure 4), for example, was isolated from a *Clavelina* sponge (0.005% wet weight) by Ireland and co-workers. Beside the unprecedented structure, wakayin (43) exhibited high *in vitro* cytotoxicity when tested against a human cancer cell line (HCT116 IC<sub>50</sub> = 0.5  $\mu$ g/mL). The mechanism of action has not been fully investigated, but it is supposed to exhibit biological activity by damaging